Multiple Myeloma | Topics

At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.

An end-of-study analysis of the LYRA trial found that patients with treatment-naïve and relapsed multiple myeloma achieved durable responses to daratumumab plus CyBorD induction followed by daratumumab maintenance therapy.